(Re)Meet Pelago: Well-Funded Quit Genius Rebrands to Make Addiction Treatment More Accessible

When we first met today’s StartUp Heatlh NOW podcast guest, he was a newly-minted doctorpreneur. After finishing med school Yusuf Sherwani, MD, teamed up with a couple fellow doctors to tackle a massive, pervasive problem they were facing in their clinics: Day after day they were seeing patients struggling with addiction, whether smoking or drinking or opioids. These were people stigmatized by their addictions into fear and inaction or they’d reached out for help and found the options unsuccessful.

This group of physicians thought, with today’s technology and breakthroughs in addiction management, there has to be a better way. So they built Quit Genius, the world’s first virtual clinic for substance use management. They combined the best digital health tools with leading cognitive behavioral therapy and medication assisted treatment.

Their solution met a hungry market. Since inception, Dr. Sherwani and his team – who joined StartUp Health in 2020 – have helped more than 750,000 people manage their substance use, and with $77 million raised, they are poised to scale even further.

We wanted to sit down with Dr. Sherwani to hear their scale-up vision and also to get the story behind their recent rebrand to Pelago. In this episode, Dr. Sherwani explains the name change – it’s derived from the word archipelago – and shares where this growing company is heading next.

  Founders: Health Transformer University fuels your health moonshot  

Funders: Become a Health Moonshot Champion Want more content like this? You can subscribe to the podcast as well as other health innovation updates at startuphealth.com/content. Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Looking to break down health barriers? If you’re an entrepreneur or investor, contact us to learn how you can join our Health Equity Moonshot. Passionate about Type 1 diabetes? If you’re an entrepreneur or investor, contact us to learn how you can join our T1D Moonshot.